Context: Vitiligo is a chronic, benign, but emotionally frustrating autoimmune disorder of depigmentation, with an incidence of 0.25-2.5% in India, the treatment of which is equally frustrating to the patient, as well as the doctor. Phototherapy is the first line treatment in many cases, which needs to be given at frequent sittings for long periods of time. As there is no satisfactory, short term treatment, many vitiligo patients, though enthusiastic in the beginning, become defaulters after a few weeks or months.
Aims: This study was conducted to assess the compliance to phototherapy (PUVA and NB-UVB), determine the reasons for non-compliance, to calculate the overall response to phototherapy and to know about the patients' perception about improvement of lesions.
Materials And Methods: All files of the patients who attended phototherapy for Vitiligo in the department for a period of 4 years from January 2007 were analyzed and the patients were contacted via mail or telephone and were made to answer questionnaire regarding their disease.
Conclusions: At the end of this retrospective questionnaire based study we concluded that only a quarter of the patients underwent regular phototherapy, among which the younger patients and those with widespread disease and facial lesions were more compliant. Educational status and sex had no impact on default status.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726895 | PMC |
| http://dx.doi.org/10.4103/0019-5154.113944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dietary Interventions, Supplements, and Plant-Derived Compounds for Adjunct Vitiligo Management: A Review of the Literature.
Nutrients
January 2025
Department of Dermatology, Weill Cornell Medicine, New York City, NY 10021, USA.
Vitiligo is a chronic autoimmune pigmentation disorder shaped by a complex interplay of genetic predispositions and environmental triggers. While conventional therapies-phototherapy, corticosteroids, and immunosuppressants-can be effective, their benefits are often partial and temporary, with recurrence common once treatment stops. As such, there is increasing interest in exploring complementary approaches that may offer a more sustainable impact.
View Article and Find Full Text PDFCombination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.
JAMA Dermatol
January 2025
CNRS, Immuno ConcEpT, UMR 5164, University Bordeaux, Bordeaux, France.
Importance: Vitiligo is a chronic autoimmune disorder leading to skin depigmentation and reduced quality of life (QOL). Patients with extensive and very active disease are the most difficult to treat.
Objective: To assess the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo.
Vitiligo Exchange: An Expert Panel Discussion of Two Clinical Cases.
J Clin Aesthet Dermatol
December 2024
Dr. Grimes is the Founder and Director at the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, California; Clinical Professor of Dermatology at the University of California, Los Angeles. Current President of the Global Vitiligo Foundation.
This article is based on a roundtable discussion in which three panelists review clinically relevant insights about vitiligo and discuss two cases that illustrate the multiple challenges faced by both patients and clinicians in managing this complex disease. The first is a 32-year-old White female patient with Fitzpatrick Skin Type III/IV with extensive depigmentation in the trunk area. The patient achieved 90-percent repigmentation with a combination therapy approach.
View Article and Find Full Text PDFRecalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.
J Clin Aesthet Dermatol
January 2025
Dr. Warren and Ms. Sanchez are with Derm Texas in Dallas, Texas.
Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed.
View Article and Find Full Text PDFThe Pathogenesis and Management of Vitiligo.
Cureus
December 2024
Physiology, Taibah University, Al-Madinah al-Munawarah, SAU.
Vitiligo is a common autoimmune disease that progressively destroys melanocytes in the skin, resulting in the appearance of patchy depigmentation. The aim of this review is to increase awareness towards vitiligo by providing insight on the pathogenesis and management options. Vitiligo is an acquired pigmentary skin disease, which can appear with one or a few macules.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!